Vir Biotechnology, Inc. (NASDAQ:VIR) Receives $20.88 Consensus Target Price from Analysts

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) have earned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $20.8750.

Several equities analysts recently issued reports on the company. Wall Street Zen lowered Vir Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Morgan Stanley upped their price target on shares of Vir Biotechnology from $23.00 to $27.00 and gave the company an “overweight” rating in a report on Thursday, June 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Wednesday, July 8th. Finally, Leerink Partners raised their price objective on shares of Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd.

Insider Activity

In other Vir Biotechnology news, Director Vicki L. Sato sold 22,000 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $10.05, for a total value of $221,100.00. Following the sale, the director owned 1,078,391 shares in the company, valued at approximately $10,837,829.55. The trade was a 2.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Janet Napolitano sold 3,200 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.45, for a total value of $30,240.00. Following the transaction, the director directly owned 21,216 shares of the company’s stock, valued at approximately $200,491.20. This trade represents a 13.11% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,579 shares of company stock worth $254,922 in the last three months. Company insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Avidity Partners Management LP bought a new stake in Vir Biotechnology during the 1st quarter worth about $8,512,000. Bank of America Corp DE boosted its position in Vir Biotechnology by 3.7% during the first quarter. Bank of America Corp DE now owns 965,814 shares of the company’s stock valued at $8,654,000 after purchasing an additional 34,906 shares during the last quarter. Janus Henderson Group PLC grew its stake in Vir Biotechnology by 47.9% in the first quarter. Janus Henderson Group PLC now owns 54,789 shares of the company’s stock valued at $491,000 after purchasing an additional 17,732 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of Vir Biotechnology during the 1st quarter worth approximately $24,593,000. Finally, Amundi raised its stake in shares of Vir Biotechnology by 52.8% during the 1st quarter. Amundi now owns 15,315 shares of the company’s stock worth $137,000 after purchasing an additional 5,294 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Vir Biotechnology Trading Down 0.1%

Shares of Vir Biotechnology stock opened at $9.34 on Friday. The stock’s fifty day simple moving average is $9.35 and its 200 day simple moving average is $8.85. The company has a market capitalization of $1.58 billion, a PE ratio of -2.98 and a beta of 1.62. Vir Biotechnology has a 12 month low of $4.16 and a 12 month high of $11.66.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Wednesday, May 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.84). The business had revenue of ($0.03) million during the quarter, compared to analyst estimates of $55.49 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 53.31%. During the same period in the previous year, the firm posted ($0.88) earnings per share. Analysts predict that Vir Biotechnology will post -1.81 EPS for the current fiscal year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical?stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell?based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID?19, HIV, hepatitis B, and tuberculosis.